Updates to the Australian Pharmaceutical Benefits Scheme
22 May 2023
Update
Services Australia has published a release detailing new and amended listings of medications on the Australian Pharmaceutical Benefits Scheme (PBS), effective from 1 May 2023.
Amendments have been made to a range of medications on the PBS, including the following medications:
- Methylphenidate (Ritalin® LA) being amended to allow access for adults with a retrospective diagnosis of ADHD. This includes access to capsules containing methylphenidate hydrochloride 10 mg, 20 mg, 30 mg, 40 mg, 60mg (modified release).
- Naltrexone (Naltrexone GH®) having a reduction in authority level for the treatment of alcohol dependence.
Enquiries regarding new and amended listings can be directed to the PBS at pbs@health.gov.au.
More news & views
The College welcomed close to 1,800 delegates in Perth, and over 450 delegates online, for our biggest Congress yet.
The RANZCP is backing the ‘YES’ campaign to recognise Aboriginal and Torres Strait Islander peoples through a First Nations Voice to Parliament enshrined in the Australian Constitution.
An update from RANZCP President, Associate Professor Vinay Lakra, on College activities, achievements and news.